Matthew Jacobsen, MD
Family Medicine · Lincoln, NENPI 1003913138
Payments from drug & device makers
Across 217 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$292
- Pfizer$256
- Boehringer Ingelheim$160
- Lilly USA, LLC$134
- Astellas Pharma US Inc$122
- plus $719 from 24 others
What the payments were for
- Food & beverage$3,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,474 |
| Novo Nordisk | 19 | $292 |
| Pfizer | 18 | $256 |
| Boehringer Ingelheim | 12 | $160 |
| Lilly USA, LLC | 9 | $134 |
| Astellas Pharma US Inc | 5 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $97 |
| Bayer | 6 | $80 |
| AstraZeneca | 5 | $62 |
| Novartis | 3 | $47 |
| Merck | 3 | $46 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Impulse Dynamics (USA) Inc. | 2 | $39 |
| Adlon Therapeutics L.p. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Medtronic | 1 | $15 |
| Stryker | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Abbott | 1 | $13 |
| Amgen | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,156 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $64,703 |
| EliquisApixaban | 81 | $55,097 |
| MounjaroTirzepatide | 27 | $35,097 |
| OzempicSemaglutide | 35 | $31,838 |
| XareltoRivaroxaban | 31 | $27,934 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $18,438 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,259 |
| JanuviaSitagliptin Phosphate | 15 | $12,477 |
| FarxigaDapagliflozin Propanediol | 15 | $11,481 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,538 |
| LinzessLinaclotide | 15 | $8,552 |
| EntrestoSacubitril/Valsartan | 14 | $7,390 |
| TradjentaLinagliptin | 13 | $6,783 |
| Atorvastatin Calcium | 565 | $4,452 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $160 | $71,48671 claims |
| PfizerEliquis | $256 | $55,09781 claims |
| Lilly USA, LLCMounjaro | $134 | $35,09727 claims |
| Novo NordiskOzempic | $292 | $31,83835 claims |
| MerckJanuvia | $46 | $12,47715 claims |
| AstraZenecaFarxiga | $62 | $11,48115 claims |
| AbbVieLinzess, Synthroid | $1,474 | $9,79932 claims |
| NovartisEntresto | $47 | $7,39014 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $12 | $1,41118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Allen HuntLincoln$17.2M
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Svjetlana DzikoLincoln$11K
- Eric JohnsonLincoln$10K
- Gary van ErtLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.